Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics director Scott W. Morrison received a grant of stock options covering 17,084 shares of Class A common stock. The options have an exercise price of $34.35 per share and vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, or sooner upon a change in control, subject to his continued service. After this grant, he holds options on 17,084 shares directly.
Vera Therapeutics director Andrew Cheng received a new stock option grant as part of his compensation. On the grant date, he was awarded options covering 17,084 shares of Class A Common Stock with an exercise price of $34.35 per share, all held directly.
The option vests in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided he remains in continuous service. It will also fully vest upon a change in control if he is still serving at that time. After this grant, he holds options for 17,084 shares, expiring in 2036.
Vera Therapeutics director Beth C. Seidenberg received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share. The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided she continues in service. They also fully vest if there is a change in control while she remains in service through that date.
Vera Therapeutics director Christy J. Oliger received a grant of stock options covering 17,084 shares of Class A common stock. The options have an exercise price of $34.35 per share and were granted as a compensation award, not a market purchase.
The options will vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics' 2027 annual stockholder meeting, subject to Oliger’s continuous service. They will also fully vest upon a change in control if she remains in service through that date, and expire on May 20, 2036 if not exercised.
Vera Therapeutics, Inc. reported that director James R. Meyers received a stock option grant. The award covers options to buy 17,084 shares of Class A Common Stock at an exercise price of $34.35 per share, expiring on May 20, 2036.
The option vests in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual stockholder meeting, as long as Meyers remains in continuous service. It will also vest in full upon a change in control if he continues in service through that date.
Vera Therapeutics director Kimball Hall received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share. These options expire on May 20, 2036 and are held directly.
The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided Hall remains in continuous service. They will also vest in full upon a change in control, again contingent on continuous service through that date.
Vera Therapeutics director Michael Morrissey received a grant of stock options covering 17,084 shares of Class A Common Stock. The options have a per-share exercise price of $34.35 and expire in 2036. They vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, with full vesting upon a change in control if he remains in service.
Vera Therapeutics director Patrick G. Enright received a stock option grant for 17,084 shares of Class A common stock. The option has an exercise price of $34.35 per share and expires on May 20, 2036. All 17,084 options were held directly after the grant.
The footnote states the option will vest in full on the earlier of the first anniversary of the grant date or the date of Vera Therapeutics' 2027 annual stockholder meeting, subject to continuous service. It will also vest in full upon a change in control if his service continues through that date.
T. Rowe Price Associates, Inc. filed an Amendment No. 3 to Schedule 13G/A reporting beneficial ownership of 4,573,684 shares of Vera Therapeutics Inc. common stock, representing 6.4% of the class. The filing shows sole voting power of 4,570,810 shares and sole dispositive power of 4,573,684 shares. The filing is signed May 15, 2026, and includes a statement denying that T. Rowe Price is the beneficial owner of the securities.
Vera Therapeutics, Inc. president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A common stock on May 12, 2026. The shares were sold in two tranches of 4,281 shares at a weighted-average price of $37.0868 and 14,219 shares at a weighted-average price of $36.6396, with actual prices ranging from $35.96 to $37.15. These transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on January 9, 2026. The filing also reports indirect holdings through a trust and a GRAT, which together hold more than 200,000 shares after these transactions.